Shire reveals positive outcome on Elvanse
Elvanse is indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in children aged 6 years of age and over when response to previous methylphenidate treatment is considered clinically inadequate.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) acted as the reference member state on behalf of seven other European countries participating in the procedure (Denmark, Finland, Germany, Ireland, Norway, Spain and Sweden).
At 2:07pm: [LON:SHP] Shire Pharmaceuticals Group share price was +6.5p at 1929.5p
Story provided by StockMarketWire.com